SELLAS Life Sciences Group, Inc. Net Income (Loss) Available to Common Stockholders, Basic
SELLAS Life Sciences Group, Inc. (SLS) reported Net Income (Loss) Available to Common Stockholders, Basic of -$20.70 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-03-31
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$6.60M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$7.08M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$4.61M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was -$2.40M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2021 was -$20.70M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$16.84M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$27.95M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was -$41.25M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$13.68M derived: sum of 2 quarters · filed 2022-03-31 | -$18.30M derived: sum of 3 quarters · filed 2022-03-31 | -$20.70M 10-K · filed 2022-03-31 |
| 2021-09-30 | -$7.08M 10-Q · filed 2021-11-12 | -$11.70M derived: sum of 2 quarters · filed 2021-11-12 | -$14.10M 10-Q · filed 2021-11-12 | -$17.82M derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-06-30 | -$4.61M 10-Q · filed 2021-08-12 | -$7.02M 10-Q · filed 2021-08-12 | -$10.73M derived: sum of 3 quarters · filed 2022-03-31 | -$15.21M derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | -$2.40M 10-Q · filed 2021-05-13 | -$6.12M derived: sum of 2 quarters · filed 2022-03-31 | -$10.59M derived: sum of 3 quarters · filed 2022-03-31 | -$15.02M derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$8.19M derived: sum of 2 quarters · filed 2022-03-31 | -$12.61M derived: sum of 3 quarters · filed 2022-03-31 | -$16.84M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$4.47M 10-Q · filed 2021-11-12 | -$8.90M derived: sum of 2 quarters · filed 2021-11-12 | -$13.12M 10-Q · filed 2021-11-12 | -$20.54M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$4.42M 10-Q · filed 2021-08-12 | -$8.65M 10-Q · filed 2021-08-12 | -$16.07M derived: sum of 3 quarters · filed 2021-08-12 | -$27.54M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$4.22M 10-Q · filed 2021-05-13 | -$11.64M derived: sum of 2 quarters · filed 2021-05-13 | -$23.11M derived: sum of 3 quarters · filed 2021-05-13 | -$27.20M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | -$7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$18.89M derived: sum of 2 quarters · filed 2021-03-23 | -$22.98M derived: sum of 3 quarters · filed 2021-03-23 | -$27.95M 10-K · filed 2021-03-23 |
| 2019-09-30 | -$11.47M 10-Q · filed 2020-11-13 | -$15.56M derived: sum of 2 quarters · filed 2020-11-13 | -$20.53M 10-Q · filed 2020-11-13 | -$33.85M derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | -$4.09M 10-Q · filed 2020-08-13 | -$9.06M 10-Q · filed 2020-08-13 | -$22.39M derived: sum of 3 quarters · filed 2020-08-13 | -$31.82M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$4.98M 10-Q · filed 2020-05-14 | -$18.30M derived: sum of 2 quarters · filed 2020-05-14 | -$27.73M derived: sum of 3 quarters · filed 2020-05-14 | -$36.26M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | -$13.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | -$22.76M derived: sum of 2 quarters · filed 2020-03-13 | -$31.29M derived: sum of 3 quarters · filed 2020-03-13 | -$41.25M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$9.44M 10-Q · filed 2019-11-14 | -$17.96M derived: sum of 2 quarters · filed 2019-11-14 | -$27.93M 10-Q · filed 2019-11-14 | -$37.39M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | -$8.53M 10-Q · filed 2019-08-14 | -$18.49M 10-Q · filed 2019-08-14 | -$27.95M derived: sum of 3 quarters · filed 2019-08-14 | -$32.41M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$9.96M 10-Q · filed 2019-05-15 | -$19.42M derived: sum of 2 quarters · filed 2019-05-15 | -$23.88M derived: sum of 3 quarters · filed 2019-05-15 | -$29.79M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | -$9.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | -$13.91M derived: sum of 2 quarters · filed 2019-03-22 | -$19.83M derived: sum of 3 quarters · filed 2019-03-22 | -$24.43M 10-K · filed 2019-03-22 |
| 2017-09-30 | -$4.46M 10-Q · filed 2018-11-14 | -$10.37M derived: sum of 2 quarters · filed 2018-11-14 | -$14.97M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | -$5.91M 10-Q · filed 2018-08-14 | -$10.51M 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | -$4.60M 10-Q · filed 2018-05-15 | |||
| 2016-12-31 | -$17.68M 10-K · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |